| Literature DB >> 32014844 |
Xiaoguang Lyu1, Jiming Hu2,3, Weiguo Dong1, Xin Xu4.
Abstract
BACKGROUND: Precision medicine (PM) is playing a more and more important role in clinical practice. In recent years, the scale of PM research has been growing rapidly. Many reviews have been published to facilitate a better understanding of the status of PM research. However, there is still a lack of research on the intellectual structure in terms of topics.Entities:
Keywords: correlation structure; coword analysis; evolution patterns; precision medicine; topics distribution
Year: 2020 PMID: 32014844 PMCID: PMC7055756 DOI: 10.2196/11287
Source DB: PubMed Journal: JMIR Med Inform
Figure 1Search procedure for documents in precision medicine research. DE: descriptor; TI: title; WOSCC: Web of Science Core Collection.
Figure 2Basic statistics of the sample papers from 2000 to 2018.
Figure 3The distribution of the keyword frequency in PM research.
Top 100 keywords in precision medicine research.
| Number | Keywords | Frequency |
| 1 | Biomarkers | 1018 |
| 2 | Genomics | 970 |
| 3 | Cancer | 851 |
| 4 | Therapy | 731 |
| 5 | Genetics | 684 |
| 6 | Drug | 549 |
| 7 | Target Therapy | 510 |
| 8 | Pharmacogenomics | 508 |
| 9 | Pharmacogenetics | 475 |
| 10 | Molecular | 357 |
| 11 | Breast Cancer | 333 |
| 12 | NGSa | 314 |
| 13 | Tumor | 296 |
| 14 | Prediction | 287 |
| 15 | Mutation | 281 |
| 16 | Clinical Trials | 268 |
| 17 | Gene | 259 |
| 18 | Sequencing | 242 |
| 19 | Imaging | 239 |
| 20 | Diagnostics | 223 |
| 21 | Proteomics | 211 |
| 22 | Prognosis | 209 |
| 23 | DNA | 195 |
| 24 | Phenotype | 187 |
| 25 | Oncology | 185 |
| 26 | SNPb | 173 |
| 27 | Omics | 170 |
| 28 | Pharmacology | 165 |
| 29 | Metabolism | 160 |
| 30 | Lung Cancer | 160 |
| 31 | Bioinformatics | 151 |
| 32 | Asthma | 148 |
| 33 | Chemotherapy | 147 |
| 34 | Immunotherapy | 146 |
| 35 | Stem Cell | 143 |
| 36 | MicroRNA | 137 |
| 37 | Epigenetics | 137 |
| 38 | Prostate Cancer | 135 |
| 39 | Genetic Test | 132 |
| 40 | EGFRc | 129 |
| 41 | Risk | 129 |
| 42 | Inflammation | 126 |
| 43 | GWASd | 125 |
| 44 | Polymorphism | 124 |
| 45 | Colon Cancer | 123 |
| 46 | Immune | 123 |
| 47 | Nanotechnology | 122 |
| 48 | PETe | 122 |
| 49 | Translation Medicine | 120 |
| 50 | NSCLCf | 119 |
| 51 | Heterogeneity | 118 |
| 52 | Big Data | 118 |
| 53 | Systems Biology | 117 |
| 54 | Machine Learning | 117 |
| 55 | Protein | 115 |
| 56 | Pathology | 115 |
| 57 | Genotype | 114 |
| 58 | Ethics | 111 |
| 59 | Health Care | 110 |
| 60 | Drug Development | 110 |
| 61 | Pharmacokinetics | 109 |
| 62 | Drug Delivery | 108 |
| 63 | RNA | 105 |
| 64 | Diagnosis | 105 |
| 65 | Prevention | 103 |
| 66 | Biobank | 103 |
| 67 | Biology | 102 |
| 68 | Patients | 100 |
| 69 | Diabetes | 100 |
| 70 | Theranostics | 100 |
| 71 | Metabolomics | 97 |
| 72 | Liquid Biopsy | 97 |
| 73 | Screening | 97 |
| 74 | Depression | 96 |
| 75 | Classification | 95 |
| 76 | MRI | 93 |
| 77 | Molecular Imaging | 92 |
| 78 | Brain | 91 |
| 79 | Decision Support | 91 |
| 80 | Electronic Health Records | 89 |
| 81 | Systems Medicine | 89 |
| 82 | Resistance | 88 |
| 83 | Cardiology | 87 |
| 84 | Clinical Medicine | 87 |
| 85 | Circulating Tumor Cell | 86 |
| 86 | Pancreatic Cancer | 84 |
| 87 | Companion Diagnostics | 83 |
| 88 | Nanoparticle | 83 |
| 89 | Toxicity | 81 |
| 90 | Radiology | 81 |
| 91 | Mass Spectrometry | 79 |
| 92 | Drug Resistance | 77 |
| 93 | Clinical Practice | 75 |
| 94 | Microarray | 74 |
| 95 | Cell | 73 |
| 96 | Metastasis | 72 |
| 97 | Molecular Diagnostics | 70 |
| 98 | Education | 70 |
| 99 | Gastric Cancer | 70 |
| 100 | Gene Expression | 70 |
aNGS: next-generation sequencing.
bSNP: Single Nucleotide Polymorphisms.
cEGFR: epidermal growth factor receptor.
dGWAS: genome-wide association studies.
ePET: positron emission tomography.
fNSCLC: non–small cell lung cancer.
The statistics of the correlation network in precision medicine research.
| Indicators | Value |
| Number of nodes | 244 |
| Number of edges | 9178 |
| Average degree | 75.2295 |
| Network all degree centralization | 0.6214 |
| Network all closeness centralization | 0.6685 |
| Network betweenness centralization | 0.0277 |
| Network clustering coefficient | 0.4843 |
| Density | 0.3096 |
Top 10 keywords in terms of degree centrality.
| Ranking | Keywords | Degree |
| 1 | Biomarkers | 225 |
| 2 | Genomics | 222 |
| 3 | Therapy | 220 |
| 4 | Cancer | 215 |
| 5 | Genetics | 213 |
| 6 | Drug | 208 |
| 7 | Prediction | 184 |
| 8 | Pharmacogenomics | 183 |
| 9 | Target therapy | 177 |
| 10 | Molecular | 172 |
Top 10 keywords in terms of closeness centrality.
| Ranking | Keywords | Closeness |
| 1 | Biomarkers | 0.9310 |
| 2 | Genomics | 0.9205 |
| 3 | Therapy | 0.9135 |
| 4 | Cancer | 0.8967 |
| 5 | Genetics | 0.8901 |
| 6 | Drug | 0.8741 |
| 7 | Prediction | 0.8046 |
| 8 | Pharmacogenomics | 0.8020 |
| 9 | Target therapy | 0.7864 |
| 10 | Molecular | 0.7739 |
Top 10 keywords in terms of betweenness centrality.
| Ranking | Keywords | Betweenness |
| 1 | Therapy | 0.0305 |
| 2 | Biomarkers | 0.0304 |
| 3 | Genomics | 0.0304 |
| 4 | Drug | 0.0289 |
| 5 | Genetics | 0.0283 |
| 6 | Cancer | 0.0260 |
| 7 | Pharmacogenomics | 0.0182 |
| 8 | Prediction | 0.0166 |
| 9 | Target therapy | 0.0148 |
| 10 | Gene | 0.0135 |
Figure 4Correlation structure of theme communities in PM research.
Indicators of 5 theme communities in precision medicine research.
| Community | Number of nodes | Number of edges | Total frequency | Average degree | Density |
| C1-Cancer | 76 | 1535 | 8221 | 82.8026 | 0.5386 |
| C2-Biomarkers | 53 | 652 | 5261 | 78.6792 | 0.4731 |
| C3-Genomics | 45 | 469 | 4473 | 70.7778 | 0.4737 |
| C4-Drug | 40 | 385 | 3741 | 68.375 | 0.4936 |
| C5-Therapy | 30 | 211 | 2743 | 65.7667 | 0.4851 |
Figure 5A total of 5 theme communities in precision medicine research. EGFR: epidermal growth factor receptor; NGS: next-generation sequencing; NSCLC: non–small cell lung cancer.
Figure 6The evolution of theme communities of precision medicine research over time (2009-2013). ALK: ALK Receptor Tyrosine Kinase; BRAF: v-raf murine sarcoma viral oncogene homolog B1; BRCA: BReast CAncer gene; EGFR: Epidermal growth factor receptor; HER2: Receptor tyrosine-protein kinase erbB-2; NGS: Next-generation sequencing; KRAS: Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; mTOR: The mammalian target of rapamycin; NSCLC: Non–small cell lung cancer.
Figure 7The evolution of theme communities of precision medicine research over time (2013-2018). ALK: ALK Receptor Tyrosine Kinase; BRAF: v-raf murine sarcoma viral oncogene homolog B1; CYP2C9: Cytochrome P450 2C9; EGFR: Epidermal growth factor receptor; GWAS: genome-wide association study; KRAS: Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NGS: Next-generation sequencing; NSCLC: Non–small cell lung cancer; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha.
Figure 8The relative development status and trends of 5 theme communities in the strategic diagram.